Anaptys Announces Participation in March Investor Conferences
AnaptysBio (ANAB), a clinical-stage biotechnology company specializing in immunology therapeutics, has announced its participation in three major investor conferences in March 2025. The company's leadership, including President and CEO Daniel Faga, will attend:
- TD Cowen 45th Annual Healthcare Conference in Boston (March 4)
- Leerink Partners 2025 Global Healthcare Conference in Miami (March 11)
- Barclays 27th Annual Global Healthcare Conference in Miami (March 12)
The events will feature fireside chats, presentations, and one-on-one investor meetings. Live webcasts will be available on the company's investor relations website, with replays accessible for 30 days post-events.
AnaptysBio (ANAB), una compagnia biotecnologica in fase clinica specializzata in terapie immunologiche, ha annunciato la sua partecipazione a tre importanti conferenze per investitori a marzo 2025. La leadership dell'azienda, incluso il Presidente e CEO Daniel Faga, parteciperà a:
- TD Cowen 45th Annual Healthcare Conference a Boston (4 marzo)
- Leerink Partners 2025 Global Healthcare Conference a Miami (11 marzo)
- Barclays 27th Annual Global Healthcare Conference a Miami (12 marzo)
Gli eventi includeranno discussioni informali, presentazioni e incontri individuali con gli investitori. Saranno disponibili webcast dal vivo sul sito web delle relazioni con gli investitori dell'azienda, con repliche accessibili per 30 giorni dopo gli eventi.
AnaptysBio (ANAB), una empresa biotecnológica en etapa clínica especializada en terapias inmunológicas, ha anunciado su participación en tres importantes conferencias para inversores en marzo de 2025. El liderazgo de la empresa, incluido el Presidente y CEO Daniel Faga, asistirá a:
- TD Cowen 45th Annual Healthcare Conference en Boston (4 de marzo)
- Leerink Partners 2025 Global Healthcare Conference en Miami (11 de marzo)
- Barclays 27th Annual Global Healthcare Conference en Miami (12 de marzo)
Los eventos contarán con charlas informales, presentaciones y reuniones individuales con inversores. Se ofrecerán transmisiones en vivo en el sitio web de relaciones con inversores de la empresa, con repeticiones accesibles durante 30 días después de los eventos.
AnaptysBio (ANAB)는 면역학 치료제에 전문화된 임상 단계의 생명공학 회사로, 2025년 3월에 열리는 세 가지 주요 투자자 회의에 참여한다고 발표했습니다. 회사의 리더십, 즉 사장 겸 CEO인 다니엘 파가(Daniel Faga)가 참석할 예정입니다:
- TD Cowen 제45회 연례 헬스케어 컨퍼런스 (3월 4일, 보스턴)
- Leerink Partners 2025 글로벌 헬스케어 컨퍼런스 (3월 11일, 마이애미)
- Barclays 제27회 연례 글로벌 헬스케어 컨퍼런스 (3월 12일, 마이애미)
이 행사에서는 편안한 대화, 발표 및 개인 투자자 미팅이 진행될 예정입니다. 회사의 투자자 관계 웹사이트에서 실시간 웹캐스트가 제공되며, 이벤트 이후 30일 동안 재생 가능합니다.
AnaptysBio (ANAB), une entreprise de biotechnologie en phase clinique spécialisée dans les thérapies immunologiques, a annoncé sa participation à trois grandes conférences pour investisseurs en mars 2025. La direction de l'entreprise, y compris le Président et CEO Daniel Faga, assistera à :
- TD Cowen 45th Annual Healthcare Conference à Boston (4 mars)
- Leerink Partners 2025 Global Healthcare Conference à Miami (11 mars)
- Barclays 27th Annual Global Healthcare Conference à Miami (12 mars)
Les événements comprendront des discussions informelles, des présentations et des réunions individuelles avec les investisseurs. Des webcasts en direct seront disponibles sur le site web des relations investisseurs de l'entreprise, avec des rediffusions accessibles pendant 30 jours après les événements.
AnaptysBio (ANAB), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf immunologische Therapeutika spezialisiert hat, hat seine Teilnahme an drei wichtigen Investorenkonferenzen im März 2025 angekündigt. Die Unternehmensführung, einschließlich Präsident und CEO Daniel Faga, wird an folgenden Veranstaltungen teilnehmen:
- TD Cowen 45th Annual Healthcare Conference in Boston (4. März)
- Leerink Partners 2025 Global Healthcare Conference in Miami (11. März)
- Barclays 27th Annual Global Healthcare Conference in Miami (12. März)
Die Veranstaltungen werden informelle Gespräche, Präsentationen und persönliche Investorenmeetings umfassen. Live-Webcasts werden auf der Website der Investor Relations des Unternehmens verfügbar sein, mit Wiederholungen, die 30 Tage nach den Veranstaltungen zugänglich sind.
- None.
- None.
SAN DIEGO, Feb. 27, 2025 (GLOBE NEWSWIRE) -- AnaptysBio, Inc. (Nasdaq: ANAB), a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics, today announced that Daniel Faga, president and chief executive officer of Anaptys, and/or other members of its executive leadership team, are scheduled to participate in multiple upcoming investor conferences:
TD Cowen 45th Annual Healthcare Conference, Boston, MA
- Format – Fireside chat and one-on-one investor meetings
- Date and Time – Tuesday, Mar. 4, 2025 at 1:10pm ET / 10:10am PT
Leerink Partners 2025 Global Healthcare Conference, Miami, FL
- Format – Fireside chat and one-on-one investor meetings
- Date and Time – Tuesday, Mar. 11, 2025 at 10:40am ET / 7:40am PT
Barclays 27th Annual Global Healthcare Conference, Miami, FL
- Format – Presentation and one-on-one investor meetings
- Date and Time – Wednesday, Mar. 12, 2025 at 8:30am ET / 5:30am PT
Live webcasts of the fireside chats and presentation will be available on the investor section of the Anaptys website at http://ir.anaptysbio.com/events. Replays of the webcasts will be available for at least 30 days following the events.
About Anaptys
Anaptys is a clinical-stage biotechnology company focused on delivering innovative immunology therapeutics for autoimmune and inflammatory diseases. Its lead program, rosnilimab, a depleter and agonist targeting PD-1+ T cells, is in a Phase 2b trial for the treatment of rheumatoid arthritis and in a Phase 2 trial for the treatment of ulcerative colitis. Other antibodies in its portfolio include ANB033, a CD122 antagonist, in a Phase 1 trial and ANB101, a BDCA2 modulator, entering a Phase 1 trial. Anaptys has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) and a TIM-3 antagonist (cobolimab, GSK4069889). To learn more, visit www.AnaptysBio.com or follow us on LinkedIn.
Contact:
Nick Montemarano
Executive Director, Investor Relations
858.732.0178
investors@anaptysbio.com
FAQ
When is AnaptysBio (ANAB) presenting at the TD Cowen Healthcare Conference 2025?
Where can investors watch AnaptysBio's (ANAB) March 2025 conference presentations?
Which investor conferences is AnaptysBio (ANAB) attending in March 2025?
What time is AnaptysBio's (ANAB) presentation at the Barclays Healthcare Conference 2025?
